News in AL Amyloidosis ASH 2016

SummaryAmyloidosis is a  rare but life-threatening protein misfolding disease. The early diagnosis and enrollment of patients into multicentre trials is of great importance, as is the need for intensive collaboration between multiple medical departments and experienced specialists. In the following review, the most intere sting abstracts from the annual American Society of Hematology (ASH) meeting in 2016 are presented. The topics include the limitations of established biomarkers in risk assessment and response evaluation, the introduction of a new biomarker, the comparison of different treatment sequences and the e fficacy of a multiple drug regimen in light-chain (AL) amyloidosis.
Source: Memo - Magazine of European Medical Oncology - Category: Cancer & Oncology Source Type: research